Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The investment activity ratios demonstrate a consistent trend of contraction starting in mid-2022, reaching a minimum in the first half of 2024, and subsequently entering a period of relative stability through March 2026. This overall trajectory indicates a significant decline in the efficiency with which the company utilizes its assets and equity to generate revenue, followed by a plateau at a lower operational baseline.
- Net Fixed Asset Turnover
- A sharp decline is observed in the efficiency of fixed assets, falling from a peak of 6.64 in July 2022 to a low of 2.97 by June 2024. This represents a substantial reduction in the revenue generated per unit of net fixed assets. Following this downturn, the ratio experienced a slight recovery to 3.46 in December 2024 and remained largely range-bound between 3.24 and 3.40 through the end of the analyzed period.
- Total Asset Turnover
- The total asset turnover follows a trajectory nearly identical to the net fixed asset turnover, peaking at 0.52 in July 2022 before descending to a floor of 0.25 in March 2024. The ratio then stabilized, returning to 0.30 by December 2024 and maintaining that precise level through March 2026. This pattern suggests that the broader asset base became significantly less productive in driving sales during the 2023-2024 period.
- Equity Turnover
- Equity utilization efficiency decreased from a high of 1.16 in July 2022 to a low of 0.61 in March 2024. While it showed a more pronounced recovery than the asset turnover ratios—reaching 0.72 in December 2024—it continued to fluctuate within a narrow band between 0.68 and 0.72 through March 2026. This indicates that while the company has regained some efficiency in using shareholder equity to generate revenue, it remains well below 2022 levels.
The synchronized movement of these three ratios suggests a systemic shift in the company's asset structure or revenue generation capacity. The steep decline across all metrics between late 2022 and early 2024 implies either a significant expansion of the asset base that has yet to yield proportional revenue growth or a period of declining sales against a constant asset base. The subsequent stabilization indicates that the company has reached a new equilibrium in its investment activity.
Net Fixed Asset Turnover
| Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Property, plant and equipment, net of accumulated depreciation | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Net fixed asset turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Property, plant and equipment, net of accumulated depreciation
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the net fixed asset turnover reveals a pronounced downward trend in asset efficiency followed by a period of relative stabilization. The ability to generate revenue from fixed assets declined significantly from the start of the observed period through mid-2024, before entering a plateau phase.
- Revenue Volatility
- A significant contraction in revenue is observed beginning in early 2023. After peaking at $27.7 billion in July 2022, revenues fell to a low of $13.0 billion by July 2023. While a moderate recovery occurred through 2024 and 2025, revenues remained substantially lower than the 2022 peaks, fluctuating between $13.2 billion and $17.7 billion.
- Fixed Asset Expansion
- Property, plant, and equipment, net of accumulated depreciation, exhibited a steady and consistent upward trajectory. The asset base grew from $15.1 billion in April 2022 to $19.4 billion by March 2026. This indicates a sustained commitment to capital investment and infrastructure expansion regardless of the volatility in top-line revenue.
- Net Fixed Asset Turnover Performance
- The turnover ratio experienced a steep decline, falling from 6.12 in April 2022 to a trough of 2.97 in June 2024. This deterioration was driven by the dual impact of declining revenues and an increasing asset base. Following this decline, the ratio stabilized, remaining within a narrow range of 2.97 to 3.46 from June 2024 through March 2026, suggesting that the company has reached a new operational equilibrium regarding its long-term investment utilization.
Total Asset Turnover
| Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Total asset turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of total asset turnover reveals a significant transition in operational efficiency over the observed period, characterized by an initial phase of stability, a sharp contraction, and a subsequent period of stabilization at a lower baseline.
- Initial Efficiency Phase (April 2022 – December 2022)
- During the first three quarters of 2022, the total asset turnover ratio remained relatively stable, fluctuating between 0.50 and 0.52. This period was marked by high revenue levels, peaking at 27,742 million US dollars in July 2022, which supported a higher rate of asset productivity relative to the overall asset base of approximately 183 billion to 197 billion US dollars.
- Contraction and Decline Phase (April 2023 – March 2024)
- A pronounced downward trend is observed starting in early 2023, with the turnover ratio dropping from 0.48 in April 2023 to a low of 0.25 by March 31, 2024. This decline was the result of a simultaneous decrease in revenues—which reached a trough of 13,007 million US dollars in July 2023—and an expansion of the total asset base, which peaked at 226,501 million US dollars in December 2023. The divergence between shrinking top-line performance and growing asset holdings led to a significant reduction in asset utilization efficiency.
- Stabilization and Plateau Phase (June 2024 – March 2026)
- From mid-2024 through the end of the period, the total asset turnover ratio entered a phase of stabilization, consistently hovering around 0.30. This plateau corresponds with a stabilization of total assets, which settled between 206 billion and 219 billion US dollars, and revenues that fluctuated between 13 billion and 17 billion US dollars. While the ratio recovered slightly from its 0.25 low, it remained substantially below the 2022 efficiency levels, indicating a new operational equilibrium where assets generate less revenue per dollar of investment than in the preceding years.
In summary, the total asset turnover experienced a structural shift. The initial high-efficiency period was replaced by a period of volatility and asset expansion, eventually resulting in a stabilized but lower efficiency ratio of 0.30 by the first quarter of 2026.
Equity Turnover
| Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Total Pfizer Inc. shareholders’ equity | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q1 2026 Calculation
Equity turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Total Pfizer Inc. shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of equity turnover reveals a significant shift in asset utilization efficiency over the observed period. From April 2022 to March 2026, the ratio transitioned from a peak efficiency level above 1.10 to a stabilized range between 0.61 and 0.72.
- Phase of Contraction (2022–2024)
- A consistent downward trend in equity turnover is observed starting from July 2022 (1.16) and reaching a trough in March 2024 (0.61). This decline is primarily driven by a contraction in quarterly revenues, which fell from a high of 27.7 billion USD in July 2022 to lows of approximately 13 billion USD in mid-2023. Simultaneously, shareholders' equity increased from 82.4 billion USD to a peak of 101 billion USD in April 2023, compounding the reduction in the turnover ratio.
- Stabilization and Plateau (2024–2026)
- Following the minimum point in early 2024, the equity turnover ratio entered a period of relative stability, fluctuating within a narrow band between 0.61 and 0.72. During this phase, shareholders' equity remained relatively consistent, ranging between 86 billion USD and 92 billion USD. While revenues showed moderate volatility, peaking again at 17.7 billion USD in late 2024, they did not return to the levels seen in 2022, resulting in a stabilized but lower turnover efficiency.
- Equity Base and Revenue Correlation
- The data demonstrates that the initial decline in efficiency was a result of the divergence between a growing equity base and shrinking revenues. As the equity base expanded by nearly 20% between April 2022 and April 2023 while revenues began to decline, the ability to generate sales per unit of equity diminished. The subsequent stabilization suggests that the company reached a new operational equilibrium where revenue generation and capital structure became more aligned.